NBI-6024
NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 239480-61-6
- Fòrmula: C106H180N28O34
- Peso molecular:2390.73
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nonobese diabetic (NOD) mice[2]
-
Dosage:0.005, 0.05, 0.5, 5, 10, 20 mg/kg
-
Administration:Subcutaneous injection (s.c.)
-
Result:Observed dose-dependent induction of responsiveness to the immunizing antigen at 5, 10, 20 mg/kg (tested by culturing spleen cells pooled from mice).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 239480-61-6
-
Peso molecular 2390.73
-
Fòrmula C106H180N28O34
-
Sequence Shortening
SHLVEALALVAGERG
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. D G Alleva et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69. [Content Brief]
[2]. Alleva DG, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)